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Mycobacterium tuberculosis can proficiently enter macrophages and diminish comple-
ment activation on its cell surface. Within macrophages, the mycobacterium can sup-
press macrophage apoptosis and survive within the intracellular environment. Previously, 
we have shown that complement regulatory proteins such as factor H may interfere with 
pathogen–macrophage interactions during tuberculosis infection. In this study, we show 
that Mycobacterium bovis BCG binds properdin, an upregulator of the complement 
alternative pathway. TSR4+5, a recombinant form of thrombospondin repeats 4 and 
5 of human properdin expressed in tandem, which is an inhibitor of the alternative 
pathway, was also able to bind to M. bovis BCG. Properdin and TSR4+5 were found 
to inhibit uptake of M. bovis BCG by THP-1 macrophage cells in a dose-dependent 
manner. Quantitative real-time PCR revealed elevated pro-inflammatory responses 
(TNF-α, IL-1β, and IL-6) in the presence of properdin or TSR4+5, which gradually 
decreased over 6 h. Correspondingly, anti-inflammatory responses (IL-10 and TGF-β) 
showed suppressed levels of expression in the presence of properdin, which gradually 
increased over 6 h. Multiplex cytokine array analysis also revealed that properdin and 
TSR4+5 significantly enhanced the pro-inflammatory response (TNF-α, IL-1β, and 
IL-1α) at 24 h, which declined at 48 h, whereas the anti-inflammatory response (IL-10) 
was suppressed. Our results suggest that properdin may interfere with mycobacterial 
entry into macrophages via TSR4 and TSR5, particularly during the initial stages of 
infection, thus affecting the extracellular survival of the pathogen. This study offers novel 
insights into the non-complement related functions of properdin during host–pathogen 
interactions in tuberculosis.
Keywords: complement, cytokine, properdin, macrophage, Mycobacterium tuberculosis, Mycobacterium bovis 
Bcg, phagocytosis, thrombospondin repeats
inTrODUcTiOn
Properdin is an upregulator of the alternative pathway of complement activation. In one of the three 
pathways of the complement system, the alternative pathway, the activation of the major complement 
opsonin, C3, is driven by a complex serine protease, C3bBb, also called the C3 convertase, which 
is bound to the surface of the complement-activating target. To form C3bBb, factor B associates 
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with C3b in the presence of Mg2+ and factor D, a serine protease, 
which cleaves factor B into Bb and Ba fragments producing a 
C3 convertase C3bBb (1). This complex, which has a half-life of 
90 s, is stabilized by the binding of properdin, which increases 
the half-life by 5- to 10-fold (2). Furthermore, C3b molecules are 
generated by C3bBb and deposited near to the surface-bound 
convertase leading to the opsonization of the target and forma-
tion of C5 convertase, producing C5a and C5b, leading on to the 
lytic pathway and cell lysis (3).
The monomer of human properdin (53 kDa) has a flexible rod-
like structure with a length of 26 nm and a diameter of 2.5 nm, 
composed of seven thrombospondin type I repeats (TSR). Each 
TSR is of about 60 amino acids, typically containing six con-
served cysteine residues: these occur in TSR1–TSR6 (4–6), but 
the N-terminal domain, TSR0, is truncated. TSR4 is crucial for 
binding to C3bBb and TSR5 for binding to C3bBb, suggesting 
that both TSRs may be important for stabilizing the C3 convertase 
complex (5). Recently, TSR4+5, expressed as a double domain, 
has been shown to bind to properdin ligands such as C3b and 
inhibit the alternative complement pathway (7). These studies 
demonstrate the important role that these TSRs may play in the 
alternative pathway and in their interaction with pathogens.
Properdin circulates in plasma at a concentration of about 
4–25  µg/ml existing as cyclic oligomers, dimer, trimer, and 
tetramer in a ratio of 26:54:20 (4). The dissociation and reas-
sociation of properdin upon denaturation–renaturation cycles 
stimulated by guanidine or low pH indicates properdin ratio 
stability in solution (8). The interaction between properdin 
monomers involves the N-terminal end of one monomer and 
the C-terminal end of another (9). Properdin can also bind to 
microbial surfaces of several pathogens, including Neisseria 
gonorrhoeae (10), Salmonella typhimurium lipopolysac-
charide (LPS), Neisseria meningitidis lipooligosaccharide (11), 
and Chlamydia pneumoniae (12). Binding of properdin to 
microbial surfaces results in the recruitment of fluid phase 
C3b, inducing assembly of C3 convertase C3bBb and causing 
further deposition of C3b on the pathogen surface (13–15), 
subsequently generating a C5 convertase, MAC formation, 
and cell lysis. At 10 µg/ml, recombinant properdin enhanced 
complement deposition on N. meningitidis and S. pneumoniae 
and dramatically enhanced serum lysis of these bacteria, and 
in the mouse model, significantly reduced bacteremia and 
increased survival rates (16).
Although Mycobacterium tuberculosis and its close-relative 
Mycobacterium bovis have significant interaction with com-
ponents of the innate immune system, e.g., toll-like receptors, 
complement, surfactant proteins SP-A and SP-D (17), the initial 
stages of tuberculosis pathogenesis remain poorly understood. 
Many bacteria have evolved mechanisms to evade immune 
responses: by inhibiting complement activation by proteolytic 
cleavage of complement proteins, having their own complement 
inhibitors (18), or binding complement regulatory proteins like 
factor H (15, 19).
Mycobacterium tuberculosis is a highly specialized intra-
cellular pathogen and may exploit complement proteins to 
enhance its uptake by macrophages. Although it has been 
shown that M. tuberculosis can activate all three pathways of 
the complement system (20, 21), it is unclear how the patho-
gen uses complement proteins in tuberculosis pathogenesis. 
M. tuber culosis has been shown to bind to complement receptors 
(CR) CR1, CR3, and CR4 and gain entry into macrophages (22–24). 
There is also evidence that enhanced phagocytosis of M. tuber-
culosis by human alveolar and monocyte-derived macrophages 
results from C3 opsonization (24). The ability of M. tuberculosis to 
bind to CR3 non-opsonically has also been shown which may be 
important for bacterial invasion when complement is sparse, for 
example, in the lung (25). Properdin has recently been considered 
as a pattern recognition receptor (PRR) on its own, i.e., binding 
to recognition patterns without need for prior deposition of C3b 
or C3bBb (26–28). Therefore, we investigated the role of proper-
din in tuberculosis pathogenesis, by using the model organism 
M. bovis BCG.
Here, we show, for the first time, that properdin and recombi-
nant form of TSR4+5 expressed as a two-module protein binds to 
M. bovis BCG, demonstrating its role as a soluble PRR. Properdin 
and TSR4+5 were found to inhibit the uptake of M. bovis BCG 
by macrophages during phagocytosis, altering the pro- and anti-
inflammatory cytokine response, and thus, possibly shaping the 
adaptive immune response in tuberculosis pathogenesis.
MaTerials anD MeThODs
Purification of native Properdin
The affinity columns, IgG Sepharose and anti-properdin mono-
clonal antibody Sepharose, were prepared as described previously 
(7). The IgG-Sepharose column was prepared from human 
non-immune IgG (~26  mg IgG/ml of Sepharose) coupled to 
CNBr-activated Sepharose (GE Healthcare, UK). For preparation 
of the anti-human properdin column, CNBr-activated Sepharose 
(GE Healthcare Life Sciences, UK) was used to couple to anti-
properdin mouse monoclonal antibody (2 mg/ml). One liter of 
human plasma (TCS Biosciences) containing 5 mM EDTA was 
filtered through Whatman filter paper before applying to IgG 
Sepharose to deplete C1q (which would otherwise have bound 
to the IgG on the anti-properdin Sepharose). The column was 
washed with three bed volume of HEPES buffer (10 mM HEPES, 
140  mM NaCl, 0.5  mM EDTA, and pH 7.4). Plasma was then 
applied to the monoclonal anti-properdin column and washed 
with the same HEPES buffer. Bound properdin was eluted with 
3 M MgCl2 and the peak fractions were dialyzed against HEPES 
buffer overnight at 4°C. Contaminants were further removed by 
applying the pooled protein fractions to a HiTrap Q FF-Sepharose 
(GE Healthcare) ion-exchange column, followed by washing the 
column with three bed volumes of 50  mM Tris–HCl, pH 7.5, 
50 mM NaCl, and 5 mM EDTA. Properdin did not bind to the Q 
Sepharose column and appeared in the flow-through free from 
contaminants as demonstrated by SDS-PAGE.
For the size exclusion chromatography analysis, 50 µl of the 
proteins at the concentrations varying from 0.3 mg/mL to 1.0 mg/
mL were applied to a TSKgel G2000SWXL, 5 µm, 7.8 × 300 mm 
column (Tosoh Bioscience). The column was equilibrated with 
buffer containing 50 mM sodium phosphate, pH7.0 and 300 mM 
NaCl at the flow rate 0.3 ml/min using SCL-10Avp HPLC system 
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(Shimadzu). The absorbance was detected at 230 and 280 nm. The 
Bio-Rad Gel Filtration Standard (Cat # 151-1901) were used for 
the protein molecular weight calibration of the column.
expression and Purification of Tsr4+5
The recombinant maltose-binding protein (MBP) fusion pro-
teins MBP-TSR4+5, MBP-TSR4, or MBP-TSR5 were expressed 
in Escherichia coli as described previously (7, 29). The E. coli 
BL21 bacterial cells (Life Technologies) were grown in 1 L of 
Luria–Bertani medium with 100 µg/ml ampicillin, shaking at 
37°C until an optical density at 600  nm (OD600) of between 
0.6 and 0.8 was reached. Protein expression was then induced 
in the bacterial cell culture with 0.4  mM isopropyl β-d-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3 h shaking 
at 37°C. The cells were then pelleted at 4,500  rpm, 4°C for 
10 min, lysed using 50 ml lysis buffer [20 mM Tris–HCl, pH 
8.0, 0.5  M NaCl, 1  mM EDTA, 0.25% v/v Tween 20, 5% v/v 
glycerol, 100  µg/ml lysozyme (Sigma-Aldrich), and 0.1  mM 
phenylmethanesulfonyl fluoride (Sigma-Aldrich)], and incu-
bated for 1 h at 4°C on a rotary shaker. The cell lysate was then 
sonicated using a Soniprep 150 (MSE, London, UK) at 60 Hz for 
30 s with an interval of 2 min (12 cycles) and then centrifuged 
at 13,000 rpm for 15 min at 4°C. The supernatant was diluted 
five-fold with buffer A (20  mM Tris–HCl, pH 8.0, 100  mM 
NaCl, 1  mM EDTA, and 0.25% v/v Tween 20) and passed 
through an amylose resin column (25 ml bed) (New England 
Biolabs) that was equilibrated in buffer A. The affinity column 
was washed with buffer A without Tween 20 and with 1 M NaCl, 
20 mM Tris–HCl, pH 8.0, 1 mM EDTA, followed by buffer B 
(20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA). The 
MBP-TSR4+5 fusion protein was eluted with 100 ml of buffer 
B containing 10 mM maltose (Sigma-Aldrich) (affinity elution 
buffer). Trace contaminants were further removed by applying 
the fusion protein to a DEAE Sepharose column. Thus, the affin-
ity purified fusion protein in affinity elution buffer was applied 
to the ion-exchange (5 ml bed) column and washed with three 
column volumes of low salt buffer containing 50 mM Tris–HCl, 
pH 7.5, 100 mM NaCl, 5 mM EDTA, at pH 7.5. After extensive 
washing with low salt buffer, the fusion protein eluted at 0.2 M 
NaCl using a NaCl gradient (50 mM to 1 M). The peak elutions 
were then passed through Pierce™ High Capacity Endotoxin 
Removal Resin (Qiagen) to remove LPS. Endotoxin levels were 
determined using the QCL-1000 Limulus amebocyte lysate 
system (Lonza), and the assay was linear over a range of 0.1–1.0 
EU/ml (10 EU = 1 ng of endotoxin). The endotoxin levels were 
less than 4 pg/µg of the MBP-TSR4+5.
Mycobacterial cell culture
Mycobacterium bovis BCG (Pasteur strain) were grown in liquid 
culture using Middlebrook 7H9 media (Sigma-Aldrich), sup-
plemented with 0.2% (v/v) glycerol, 0.05% (v/v) Tween-80, and 
10% (v/v) albumin dextrose catalase (ADC) (BD BBL, Becton 
Dickinson). Green fluorescent protein (GFP)-expressing M. bovis 
BCG (Danish Strain 1331) containing the pGFPHYG2 plasmid 
was a kind gift from B. Robertson, Imperial College, London, UK. 
GFP-M. bovis BCG was grown in the above conditions/media but 
with the addition of 50 µg/ml of hygromycin to maintain the plas-
mid. Cultures were incubated at 37°C with agitation (~120 rpm) 
for 7–10  days until the bacteria had reached the exponential 
growth phase at OD600nm = 0.60–1.00.
assay of human Properdin and  
Tsr4+5 Binding to Mycobacteria
Mycobacterium bovis BCG, harvested and washed in PBS, was 
adjusted to a concentration of 1.25 × 109 cells/ml in PBS (OD600 = 1 
equates to approximately 1 × 109 cell/ml). Then 200 µl of bacterial 
suspension was dispensed into individual microtiter wells of a 
96-well plate (Maxisorp™, NUNC). Plates were incubated at 
4°C overnight and washed with buffer 1 [10 mM HEPES pH 7.5, 
140  mM NaCl, 0.5  mM EDTA, and 100  µg/ml hen ovalbumin 
(Sigma-Aldrich)]. Wells were blocked for 2 h at 37°C with buffer 
1 + 10% (w/v) Marvel Dried Milk powder.
Human properdin (up to 50 µg/ml) or TSR4+5 (up to 30 µg/ml) 
were added, in two-fold serial dilutions (100 µl/well) in buffer 1 
and incubated for 2 h at 37°C. Individual TSR4 and TSR5 pro-
teins, MBP and BSA were used as negative controls. Microtiter 
wells were washed three times with buffer 1. Mouse anti-
properdin monoclonal antibody (1.19  mg/ml) diluted 1/2,500 
in buffer 1 (29) was added to the wells containing properdin. 
Mouse anti-MBP monoclonal antibody (Sigma-Aldrich) was 
added to wells containing TSR4+5, TSR4 and TSR5, diluted 
1/5,000 in buffer 1, and incubated for 1 h at 37°C. For the BSA 
negative control, mouse anti-BSA monoclonal antibody (Sigma-
Aldrich) was used (1/5,000 dilution). Plates were washed an 
additional three times in buffer 1 and then incubated with goat 
anti-mouse IgG-horseradish peroxidase conjugate (Sigma-
Aldrich), diluted 1/5,000 in buffer 1. The substrate p-nitrophenol 
phosphate (Sigma-Aldrich) was then added to each well, and the 
plates read at 405 nm.
Fluorescence Microscopy for  
Tsr4+5 Binding to Mycobacteria
Mycobacterium bovis BCG bacteria (approximately 106 cells) 
were spotted on poly-l-lysine coated microscope slides (Sigma-
Aldrich) and incubated at 37°C for cells to adhere. After washing 
three times with PBS, bacterial cells were then fixed with 4% 
paraformaldehyde for 5 min. Slides were washed three times with 
PBS and then incubated at 37°C for 1 h with 0, 1, or 10 μg/ml of 
TSR4+5, or 10 µg/ml of BSA (negative control) in buffer 1. Slides 
were washed three times with PBS, and then the primary mono-
clonal antibody (mouse anti-MBP) added at 1/500 dilution and 
incubated for 1 h at room temperature. After washing three times 
with PBS, goat anti-mouse conjugated with AlexaFluor488 (1/500 
dilution) was added as the secondary antibody and incubated for 
1 h at room temperature. Slides were then washed three times 
with PBS and mounted with antifade (Citifluor AF3) PBS solu-
tion and viewed using a LeicaDM4000 Fluorescence microscope. 
Images were processed using Image J.1
1 http://imagej.nih.gov/ij.
TaBle 1 | Primers used for quantitative real-time PCR.
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Phagocytosis assay
THP-1 macrophage cells were cultured in RPMI-1640 (Gibco) 
(RPMI) containing 10% (v/v) fetal bovine serum (FBS) (Sigma-
Aldrich), 2 mM l-glutamine (Sigma-Aldrich), 100 U/ml penicil-
lin (Sigma-Aldrich), 100  µg/ml streptomycin (Sigma-Aldrich), 
and 1 mM sodium pyruvate (Sigma-Aldrich) and left to grow in 
5% CO2 at 37°C for approximately 3 days before passaging. Cells 
were resuspended in RPMI and adjusted to 1 × 106 cells/well (in 
1.8 ml) in a 24-well plate. To induce adherence onto the wells, 
THP-1 cells were treated with 50 ng/ml of phorbol 12-myristate 
13-acetate (PMA) (Sigma-Aldrich) into RPMI-1640 without FBS, 
penicillin or streptomycin and left to settle for at least 30  min 
before adding 200 µl of bacterial culture (1 × 109 bacteria/ml).
M. bovis BCG bacteria were pelleted at mid-exponential 
phase, at an OD600nm = 0.6–1.0 by centrifugation at 1,000 × g for 
10 min at 4°C. The mycobacterial pellet was resuspended in the 
buffer 1. This mycobacterial culture was then separated into dif-
ferent microfuge tubes and treated with varying concentrations 
of properdin (2 or 20  µg/ml) or MBP-TSR4+5 (1 or 5 µg/ml). 
Control samples were left untreated, and all were incubated for 2 h 
at 37°C for binding to occur. The mycobacterial suspension was 
washed once in growth medium before resuspending in RPMI 
medium without FBS, penicillin, or streptomycin. 200 µl of the 
mycobacterial suspension was added to each well of THP-1 cells. 
Mycobacterial concentration was adjusted to give approximate 
multiplicity of infection (MOI) ratio of 10:1.
Plates were gently swirled and incubated at 37°C, 5% CO2 
for up to 48 h to allow mycobacterial uptake. THP-1 cells were 
sampled at 15, 30, and 45 min and 1, 2, and 6 h. Supernatants were 
collected after 24 and 48 h of incubation for multiplex analysis. 
Plates were washed three times with PBS to remove extracellular 
bacteria. THP-1 cells were then lifted by adding 1 ml of 0.25% 
trypsin to the wells and incubated for 10 min at 37°C, 5% CO2. 
THP-1 cells were collected by centrifugation at 1,000  ×  g for 
10 min at 4°C.
To recover and count the ingested mycobacteria, THP-1 cells 
were lysed by resuspending the cell pellets in 1 ml of sterile water, 
followed by a series of vortex mixing for 10 min at room tempera-
ture. 24-well plates containing 2 ml Middlebrook 7H10 agar with 
10% Oleic Acid+ADC (OADC) (BD, BBL, Becton Dickinson) 
were prepared. Four serial 1/10 dilutions were made, and 10 µl of 
the concentrated mycobacterial suspension and diluted suspen-
sion from each time point was spotted onto the 7H10 agar wells. 
The 24-well plates were secured with parafilm and wrapped in 
aluminum foil, inverted and incubated at 37°C for 10–14 days. 
Wells were photographed, and the colony-forming unit (CFU) 
count determined. The same procedure was used to quantify the 
initial input number of bacteria incubated with THP-1 cells.
Fluorescence Microscopy  
for Phagocytosis assay
THP-1 cells were cultured as described above and seeded at 
1 × 105 cells per 13 mm coverslip and differentiated with PMA 
as described above. GFP-expressing M. bovis BCG was incubated 
with 0, 1, 10 µg/ml of TSR4+5 for 2 h at 37°C in buffer 1. Cells 
were also incubated with 10 µg/ml of BSA as a negative control. 
Cells were washed twice in PBS and then resuspended in plain 
RPMI media. 1 × 106 GFP-M. bovis BCG was added to the THP-1 
cells (MOI of 10:1) and incubated for phagocytosis for 2 h at 37°C. 
THP-1 cells were then washed three times in PBS to remove 
extracellular bacteria and then fixed in 4% paraformaldehyde 
for 5 min. After washing three times in PBS, THP-1 cells were 
incubated with 2 µg/ml of AlexaFluor546-conjugated wheat germ 
agglutinin (Invitrogen) to reveal the plasma membrane. Cells 
were then washed three times and mounted using Vectashield 
antifade with DAPI (Vector Labs) to reveal nucleus. Slides were 
observed under a Leica DM4000 fluorescence microscope at 40× 
magnification. Images were processed using Image J (see text 
footnote 1).
Quantitative real-Time Pcr (qPcr) 
analysis of mrna expression of cytokines
THP-1 cell pellets were collected from each time point as described 
above. RNA extraction was performed using the GenElute 
Mammalian Total RNA Purification Kit (Sigma-Aldrich) accord-
ing to the manufacturer’s protocol. Samples were then treated 
with DNase I (Sigma-Aldrich) to remove any contaminating 
DNA according to the manufacturer’s protocol. The amount of 
RNA was measured using the NanoDrop 2000/2000c spectro-
photometer (Thermo Fisher Scientific) at 260 nm, and the ratio of 
absorbance at 260 and 280 nm was used to assess the purity of the 
RNA. Complementary DNA (cDNA) was synthesized using High 
Capacity RNA to cDNA Kit (Applied Biosystems, UK) according 
to the manufacturer’s protocol. Primer sequences (Table 1) were 
designed and analyzed for specificity using the nucleotide Basic 
Local Alignment Search Tool and Primer-BLAST.2
PCR was performed on all cDNA samples to assess the 
quality of the cDNA. The qPCR assays were performed for the 
expression of pro- and anti-inflammatory cytokines. The qPCR 
reaction consisted of 5 µl Power SYBR Green MasterMix (Applied 
Biosystems), 75 nM of forward and reverse primer, 500 ng tem-
plate cDNA in a 10 µl final reaction volume. qPCR was performed 
in a 7900HT Fast Real-Time PCR System (Applied Biosystems). 
The initial steps were 2  min incubation at 50°C followed by 
10 min incubation at 95°C, the template was then amplified for 
40 cycles under these conditions: 15  s incubation at 95°C and 
1  min incubation at 60°C. Samples were normalized using the 
expression of human 18S rRNA. Data were analyzed using the 
relative quantification (RQ) Manager Version 1.2.1 (Applied 
Biosystems). Cycle threshold (Ct) values for each cytokine target 
2 http://blast.ncbi.nlm.nih.gov/Blast.cgi.
FigUre 1 | Purified human properdin and recombinant maltose-binding protein (MBP)-thrombospondin repeats (TSR) 4+5. (a) Properdin was purified from human 
plasma. Filtered plasma was applied to a non-immune IgG-Sepharose column, then to a mouse monoclonal anti-properdin Sepharose column; properdin was 
eluted with 3 M MgCl2. The eluted samples were dialyzed against HEPES buffer (10 mM HEPES, 140 mM NaCl, 0.5 mM EDTA, pH 7.4) overnight at 4°C. 
Contaminants were removed by applying the protein to a Q Sepharose column, and the product appears as a single band on SDS-PAGE and western blot at about 
55 kDa. (B) MBP-TSR4+5 was purified via an amylose resin column, and the purified fusion protein also appears on SDS-PAGE as a band of about 55 kDa.
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gene were calculated, and the relative expression of each cytokine 
target gene was calculated using the RQ value, using the formula: 
RQ = 2−ΔΔCt for each cytokine target gene, and comparing relative 
expression with that of the 18S rRNA constitutive gene product. 
Assays were conducted twice in triplicate.
Multiplex analysis
Supernatants were collected from the phagocytosis assay at 24 
and 48  h to determine the levels of secreted cytokines (IL-6, 
IL-10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, 
IL-17A, IL-9, and TNF-β), chemokines (MCP-3, MDC, Eotaxin, 
Fractalkine, GRO, IL-8, IP-10, MCP-1, and MIP-1α), growth fac-
tors (IL-2, EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7, and 
VEGF), and other related ligands and receptors (IFN-α2, IFN-ϒ, 
FLT-3L, IL-1RA, and sCD40L). MagPix Milliplex kit (EMD 
Millipore) was used to measure immune response following the 
manufacturer’s protocol. 25 µl of assay buffer was added to each 
well of a 96-well plate, followed by the addition of 25 µl of standard, 
controls or supernatants of cells treated with M. bovis BCG in the 
presence or absence of properdin and MBP-TSR4+5. 25 µl of mag-
netic beads coupled to analytes of interest was added in each well 
and incubated for 18 h at 4°C. The 96-well plate was washed with 
the assay buffer, and 25 µl of detection antibodies was incubated 
with the beads for 1 h at room temperature. 25 µl of streptavidin– 
phycoerythrin was then added to each well and incubated for 
30 min at room temperature with shaking at 750 rpm. Following 
a washing step, 150 µl of sheath fluid was added to each well, and 
the plate was read using the Luminex Magpix instrument. Assays 
were conducted in duplicate.
statistical analysis
Analysis of data for statistical significance was conducted using 
GraphPad Prism 6 for Windows (GraphPad Software, Inc.). 
Statistical analyses were made using two-way ANOVA for mRNA 
expression data and a one-way ANOVA for the multiplex data. 
p Values < 0.05 were considered statistically significant, unless 
otherwise stated (non-significant).
resUlTs
human Properdin and Tsr4+5  
Bind to Mycobacteria
Human properdin was purified from human plasma. SDS-PAGE, 
followed by western blotting using antihuman properdin poly-
clonal antibodies, showed a distinct band at 55 kDa (Figure 1A), 
which was the expected molecular weight of the glycosylated 
monomer. The two biologically active modules of properdin 
TSR4 and TSR5 were expressed together in tandem as previously 
described, fused to MBP (7), and is also shown on an SDS-PAGE 
gel, which has a molecular weight of 55 kDa (Figure 1B). Using 
gel filtration chromatography, we found that human properdin 
eluted as a mixture of monomer, dimer and trimer; a negligible 
amount probably formed aggregates. Nearly 60% of MBP-TSR4+5 
appeared as a monomer while nearly 40% was found to migrate as 
a dimer (data not shown).
The binding of properdin to M. bovis BCG was observed to 
be in a dose-dependent manner; BSA was used as a negative 
control that showed almost no binding (Figure  2A). TSR4+5 
binding was also observed to be in a dose-dependent manner. 
MBP was used as a negative control (Figure 2B). The two binding 
curves cannot be compared quantitatively, as different detection 
antibodies were used. Because the MBP-TSR4+5 recombinant 
protein and properdin monomer have about the same molecular 
weight, 5 µg of TSR4+5 corresponds in molar terms to about 5 µg 
of properdin monomer (Figures 1A,B). The binding of a mixture 
of the two separately expressed TSR4, and TSR5 is much lower 
than that of the combined expressed TSR4+5 (Figure 2B). For 
this comparison, the same detection antibody was used. These 
results suggest that both TSR4 and TSR5 modules contribute 
to the interaction with M. bovis BCG, and that TSR4+5 binds 
FigUre 2 | Human properdin binds mycobacteria via thrombospondin 
repeats (TSR) 4+5. (a) Properdin binding to mycobacteria; BSA was used as 
a negative control protein. (B) Comparison between TSR4+5 and individual 
TSR4 and TSR5 binding to mycobacteria; maltose-binding protein (MBP) as 
negative control. Assays were conducted in 10 mM HEPES, 140 mM NaCl, 
0.5 mM CaCl2 + 0.5 mM MgCl2, 100 µg/ml hen ovalbumin, and pH 7.5. 
Serial dilutions of properdin were incubated in mycobacteria coated wells 
followed by incubation with mouse anti-properdin monoclonal antibody and 
mouse anti-BSA monoclonal antibody, respectively; serial dilutions of 
TSR4+5, TSR4 or TSR5 were incubated in another set of mycobacteria 
coated wells followed by incubation with mouse anti-MBP monoclonal 
antibody. Anti-mouse IgG conjugated with alkaline phosphatase and 
substrate p-nitrophenol phosphate were incubated in both sets of wells, and 
the color was measured at 405 nm using a plate reader. Assay was 
conducted in quadruplicate. Error bars represent SD. (c) Differential direct 
binding of 0, 1, and 10 µg/ml of TSR4+5 to Mycobacterium bovis BCG. 
10 µg/ml of BSA was used as a negative control. Cells were incubated for 
2 h with either TSR4+5 or BSA. Cells were washed, fixed, and stained with 
mouse anti-MBP monoclonal antibody followed by goat anti-mouse 
1gG-conjugated with AlexaFluor488. Images are shown as single sections 
taken using a Leica DM4000 microscope; bar scale 10 µm.
FigUre 2 | Continued
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with similar characteristics to that of whole properdin on 
M. bovis BCG surface. These results were further confirmed using 
microscopy where TSR4+5 specifically bound to M. bovis BCG in 
a dose-dependent manner (Figure 2C).
Properdin inhibits Uptake of M. bovis  
Bcg by ThP-1 cells
Properdin inhibited the uptake of M. bovis BCG by THP-1 
cells. At a concentration of 20 µg/ml, uptake of  M. bovis BCG 
was significantly reduced by properdin (Figure  3A). TSR4+5 
was also able to substantially inhibit uptake of M. bovis  
BCG by THP-1 cells (Figure  3B). The effect of properdin and 
TSR4+5 on the phagocytosis of M. bovis BCG was dose depend-
ent. The input number of M. bovis BCG was about 7.8 × 106 CFU/
ml, which was the total number of bacteria added to THP-1 
cells. Without properdin or TSR4+5, 5.0  ×  106  CFU/ml of M. 
bovis BCG was phagocytosed which was approximately 66% 
efficiency of phagocytosis compared with the input number. 
At the highest concentration tested, properdin showed an 
inhibition of uptake of approximately 60% compared with 
M. bovis BCG with no properdin (Figure  3A). For TSR4+5, 
the effect on M. bovis BCG was slightly lower at approxi-
mately 40% inhibition (Figure  3B). These results were also 
confirmed by microscopy, with TSR4+5 having a suppres-
sive effect on the uptake of GFP-expressing M. bovis BCG 
by THP-1 cells (Figure  3C). PMA stimulation was used to 
induce differentiation of THP-1 cells before incubation with 
M. bovis BCG. PMA has been shown to activate protein kinase 
C and increase cell adherence and expression of surface mark-
ers associated with macrophage differentiation (30). These data 
show that (i) properdin has an anti-opsonic effect on M. bovis 
BCG, inhibiting phagocytosis; and (ii) TSR4+5 modules play a 
major role in this interaction of M. bovis BCG and macrophages. 
These observations demonstrate, for the first time, a novel, 
non-complement-related role for properdin in host–pathogen 
interactions in tuberculosis.
Properdin induces a Pro-inflammatory 
response During the early Phase of 
Phagocytosis of M. bovis Bcg by  
ThP-1 cells
The effect of properdin on the inflammatory response during the 
phagocytosis of M. bovis BCG was measured. The gene expres-
sion of key pro- and anti-inflammatory cytokines in tuberculosis 
was determined using quantitative real-time PCR. Our data 
showed that properdin significantly enhanced the upregulation of 
pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 from THP-1 
cells challenged by M. bovis BCG (Figure 4A), particularly at the 
FigUre 3 | Continued
FigUre 3 | Effect of properdin and thrombospondin repeats (TSR) 4+5 on 
the phagocytosis of Mycobacterium bovis BCG by THP-1 cells. (a) M. bovis 
BCG was treated with properdin at concentrations of 0, 2, and 20 µg/ml or 
with (B) TSR4+5 at concentrations 0, 1, and 5 µg/ml. The mycobacteria 
were incubated with macrophage for 2 h. After THP-1 cell lysis, surviving 
internalized M. bovis BCG were measured by plating lysates on 7H10 media 
to obtain colony-forming units (CFUs). The input value is the starting number 
of M. bovis BCG added to the THP-1 cells, before phagocytosis. A one-way 
ANOVA test was performed on the data to determine significant differences 
in CFU count by properdin or TSR4+5. All comparisons were significant 
(p < 0.05), unless where shown (ns, not significant, p > 0.05). Samples were 
analyzed in triplicate. (c) Differential uptake of GFP-M. bovis BCG by THP-1 
macrophages after treatment with 0, 1, and 10 µg/ml of TSR4+5, or 10 µg/
ml of BSA, used as a negative control. Cells were incubated for 2 h. Cells 
were then washed, fixed, and stained with AlexaFluor546-conjugated wheat 
germ agglutinin to reveal the plasma membrane (red), and the nucleus was 
stained with DAPI (blue). Images are shown as single sections, taken using a 
Leica DM4000 microscope; bar scale 10 µm.
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anti-inflammatory cytokines measured from THP-1 cells (IL-10 
and TGF-β) were shown to be downregulated in the presence of 
properdin, when challenged by M. bovis BCG (Figure 4B). IL-12 
also appeared to be downregulated (Figure  4A). Properdin, 
therefore, appears to play an important role in pro-inflammatory 
cytokine production by macrophages infected by M. bovis BCG, 
which may have significant implications in shaping the adaptive 
immune response during M. tuberculosis infection.
Cytokine gene expression by THP-1 cells infected with M. bovis 
BCG were also studied in the presence of TSR4+5, which 
revealed that TSR4+5 also has a significant effect on the pro- 
inflammatory response. TNF-α was upregulated (Figure  5A), 
while IL-10 was found to be downregulated (Figure  5B), dur-
ing the first hour of phagocytosis. IL-12 was also shown to be 
significantly downregulated (Figure 5A). These data mirror the 
observations for properdin, and hence, validate the importance 
of TSR4+5 in the binding of properdin to M. bovis BCG and in 
its modulation of the inflammatory response. These data are also 
similar to recent published observations of another complement 
regulatory protein, factor H (19), thus offering potentially novel 
insights into the involvement of these proteins in host–pathogen 
interactions in tuberculosis.
Multiplex analysis of cytokine secretion
The inflammatory response during the phagocytosis of M. bovis 
BCG by THP-1 cells was further determined by measuring the 
secretion of cytokines, chemokines, and other growth factors 
using the Multiplex analysis of supernatants collected at 24 
and 48  h post phagocytosis (Figures  6A–D). The secretion 
of pro-inflammatory cytokines TNF-α, IL-1β, and IL-1α was 
significantly enhanced by treatment with properdin or TSR4+5 
at the 24 h time point (Figure 6A). The enhancement of these 
pro-inflammatory cytokines can be critical for controlling 
mycobacterial infection, particularly in the formation of the 
granuloma. However, by 48  h, there was a decrease in the 
production of pro-inflammatory cytokines (IL-6, IL-12p40, 
IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, and IL-9) in the 
presence of properdin- and TSR4+5-treated M. bovis BCG 
(Figure  6A). Properdin and TSR4+5 also downregulated the 
initial stage of uptake (within the first hour of phagocytosis), 
which decreased gradually toward the later stages of phagocy-
tosis. The increase in TNF-α transcript was particularly striking 
as TNF-α is well known for activating macrophages for killing of 
intracellular mycobacteria. In addition, TNF-α is a key media-
tor in the early stages of granuloma formation. By contrast, the 
FigUre 4 | Temporal mRNA expression profile of cytokines produced by THP-1 cells incubated with different concentrations of properdin and Mycobacterium bovis 
BCG. (a) Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and IL-12; (B) anti-inflammatory cytokines: TGF-β and IL-10. The expression of each cytokine was 
measured using qPCR, and the relative expression [relative quantification (RQ)] calculated by normalizing the data using human 18S rRNA expression as a control. 
The RQ value was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted twice in triplicates. Error bars represent SD. A two-way ANOVA test was 
performed on the data to determine significant differences in expression of cytokine production by properdin. All comparisons were significant (p < 0.05), unless 
where shown (ns, not significant, p > 0.05).
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anti-inflammatory response such as IL-10 after 24 and 48 h of 
phagocytosis, although this was less pronounced for IL-12 at 
48  h (Figure  6A). These observations again mirror the initial 
responses observed in cytokine gene expression of during the 
first few hours of phagocytosis, in the presence of properdin or 
TSR4+5 (Figures 5A,B). The effect of properdin and TSR4+5 
also led to marked downregulation of a number of growth 
factors MCP-3 (24 h), MDC, Eotaxin, Fractalkine (24 h), GRO 
FigUre 5 | Temporal mRNA expression profile of cytokines produced by THP-1 cells incubated with different concentrations of thrombospondin repeats (TSR) 4+5 
and Mycobacterium bovis BCG. (a) Pro-inflammatory cytokines: TNF-α and IL-12; (B) anti-inflammatory cytokine: IL-10. The expression of each cytokine was 
measured using qPCR, and the relative expression [relative quantification (RQ)] calculated by normalizing the data using human 18S rRNA expression as a control. 
The RQ value was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted twice in triplicates. Error bars represent SD. A two-way ANOVA test was 
performed on the data to determine significant differences in expression of cytokine production by TSR4+5. All comparisons were significant (p < 0.05), unless 
where shown (ns, not significant, p > 0.05).
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(24  h), IP-10, MCP-1, MIP-1, VEGF, G-CSF (48  h), GM-CSF 
(48 h), and VEGF (24 h) (Figures 6B,C). Additional ligands and 
receptors (IFN-α2, IFN-γ, FLT-3L, IL-1RA, and sCD40L) did 
not show any significant changes (Figure 6D).
DiscUssiOn
We have previously shown that a complement regulatory protein, 
factor H, can bind to M. bovis BCG and inhibit its uptake by 
THP-1 macrophages (19). Factor H can also enhance the pro-
inflammatory response during this host–pathogen interaction 
(19). This study highlighted a novel complement-independent 
property of factor H as an anti-opsonin and in the modulation of 
the inflammatory response against a pathogen. With the goal of 
further elucidating the role of complement control proteins in the 
early stages of mycobacterial infection, this study looked at the 
role of properdin, an upregulator of the alternative complement 
pathway. Properdin and thrombospondin repeat (TSR) modules 
TSR4+5 were shown to bind to M. bovis BCG and inhibit bacterial 
uptake by THP-1 cells, augmenting the inflammatory response. 
These observations are similar to what has been observed previ-
ously with factor H (19), which is intriguing, since properdin and 
factor H have opposing effects on the regulation of complement 
activation (3). These findings were also consistent with previous 
reports, which have demonstrated that properdin deficient mice 
have a reduced M1 (IL-1β) and increased M2 (arginase-1, MCP-
1, IL-10) profile, crucial for the tumor microenvironment (31). 
This suggests that the production of IL-1β and reduction in IL-10 
mediated by properdin may be required for protection against M. 
tuberculosis in the initial phase of infection.
The functions of properdin have been extensively investigated 
within the remit of the complement alternative pathway, and 
FigUre 6 | Continued
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FigUre 6 | Multiplex cytokine analysis of supernatants collected at 24 and 48 h phagocytosis of Mycobacterium bovis BCG by THP-1 cells incubated with or 
without properdin and thrombospondin repeats (TSR) 4+5. The supernatants were collected from phagocytosis assay of M. bovis BCG in the presence or absence 
of properdin and TSR4+5 at 24 and 48 h time point. The levels of cytokine production were measured for (a) (IL-6, IL-10, IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, 
IL-13, IL-15, IL-17A, IL-9, and TNF-β), (B) chemokines (MCP-3, MDC, Eotaxin, Fractalkine, GRO, IL-8, IP-10, MCP-1, and MIP-1α), (c) growth factors (IL-9, IL-2, 
EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7, and VEGF), and (D) related ligands and receptors (IFN-α2, IFN-γ, FLT-3L, IL-1RA, and sCD40L) using multiplex 
analysis. Error bars represent SD. A one-way ANOVA test was performed on the data to determine significant differences in expression of cytokine production by 
properdin or TSR4+5. All comparisons were significant (p < 0.05), unless where shown (ns, not significant, p > 0.05). Supernatants were analyzed in duplicate.
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its involvement with pathogens has largely been characterized 
as complement dependent. In this study, we aimed to look at 
the complement-independent interaction of properdin with 
mycobacteria (i.e., effects in the absence of other complement 
proteins), with a view to examining its possible role in the patho-
genesis of tuberculosis. The role of complement in tuberculosis 
has been examined, but little is understood about the role of 
the individual complement proteins in tuberculosis infection, 
especially complement control proteins. Properdin has been 
shown to play a role in a number of pathogenic infections 
such as those by C. pneumoniae, in which properdin promotes 
complement C3b deposition and opsonization (12). A recent 
study also demonstrated that a low dose of properdin, which 
is highly polymerized, is able to protect against N. meningitidis 
and Streptococcus pneumoniae, by assembling the alternative 
complement pathway (16). The central premise in these recent 
studies is that properdin is an upregulator of the complement 
alternative pathway, and thus, when in contact with pathogens, 
the alternative pathway is triggered and stabilized by properdin.
Properdin has also been shown to enhance the uptake of apop-
totic T cells by dendritic cells (DCs) and macrophages, thus pro-
moting phagocytosis (27). Properdin may also bind to the DNA 
found to be exposed on apoptotic and necrotic cells, suggesting 
that this may also be a crucial site for alternative pathway activation 
(32). There is recent evidence to suggest that properdin, locally 
produced by tolerogenic DCs, binds to necrotic cells, confirming 
its role a pattern recognition molecule of the innate immunity. In 
addition, properdin is also involved in the interaction of DC and 
T cell responses. Interestingly, silencing of properdin by treating 
DCs with siRNA in the presence/absence of IFN-γ reduced the 
proliferation of allogenic T  cells (33). Properdin binds to early 
apoptotic cells via sulfated GAGs, resulting in C3b deposition and 
uptake by phagocytes. Activation of neutrophils drives the deposi-
tion of properdin, which binds apoptotic T cells. Since properdin 
has been shown to bind apoptotic cells via GAGs (27) or DNA, 
it remains unclear what other ligands and receptors are involved 
in properdin–apoptotic cell interaction. It is likely that properdin 
as a soluble factor is acting as an adaptor molecule. Furthermore, 
properdin also binds to NKp46 expressed on natural killer cells, 
innate lymphoid cells (ILC)1 and ILC3. This study demonstrated 
that the control of meningococcal infection was dependent on 
NKp46 and group 1 ILCs, further elucidating the role of properdin 
as an independent pattern recognition molecule (34).
In our study, we show that purified native properdin and 
TSR4+5 bind to M. bovis BCG in a dose-dependent manner, 
suggesting that the binding of properdin to M. bovis BCG may 
be via TSR4+5. The physiological concentration of properdin in 
serum is about 25 µg/ml (35). We also demonstrate that coating of 
M. bovis BCG with properdin inhibits the uptake of the bacterium 
by THP-1 cells; however, only about 60% inhibition was achieved 
at the highest dose of native properdin. TSR4+5 was also able to 
mirror the effects of properdin, in inhibiting the uptake of M. 
bovis BCG by macrophages by up to 40%.
The recruitment of properdin by mycobacteria may be particu-
larly crucial in the initial stages of tuberculosis infection, when 
after inhalation, the first host cell M. tuberculosis encounters is 
the alveolar macrophage.
In the lungs, mycobacteria are phagocytosed by alveolar 
macro phages, which are unable to completely eliminate them, 
and so produce crucial chemoattractants (36), which recruit 
inflammatory cells such as neutrophils, macrophages, γδ-T cells, 
and natural killer cells that stimulate inflammation and tissue 
remodeling (36–38). Our findings may be indicative of the 
early inflammatory processes in  vivo, involved in granuloma 
formation, which are nodular-type lesions that cordon-off M. 
tuberculosis infection, and provide an environment for the bacilli 
to persist and survive as a latent infection. TNF-α and IFN-γ are 
involved in recruitment of cells in the granuloma (39, 40). Thus, 
properdin may play a role in granuloma formation by promoting 
pro-inflammatory cytokines. Inflammatory balance is essential 
particularly of Th2/Th1 cytokines, which are required to maintain 
a protective granuloma (41). This is determined by the balance 
in IFN-γ/TNF-α versus IL-4/IL-10/TGF-β within the granuloma. 
Properdin and TSR4+5 may be implicated in maintaining this 
balance. It is not known whether complement proteins reside in 
the granuloma; however, during infection, complement proteins 
may be produced locally at sites of infection. Properdin may be 
secreted by neutrophils, monocytes and T cells locally at the site 
of infection (3). Thus, innate immune molecules residing in or 
being recruited at sites of infection may play a role in the balance 
of Th1/Th2, which may cause granuloma necrosis and replication 
of M. tuberculosis (41–43).
TNF-α was dramatically increased in the first 24 h of phago-
cytosis in the presence of properdin and TSR4+5, compared 
to non-treated mycobacteria. TNF-α plays a major role in 
granuloma formation and our results suggest that properdin may 
have a role in potentiating the pro-inflammatory response that 
results in granuloma formation. These observations are further 
strengthened by the concurrent increase in IL-1α levels over 24 h 
which have been shown to be key in macrophage proliferation 
and maturation during granuloma formation (44).
During phagocytosis, pro- and anti-inflammatory 
cytokines were produced by THP-1 cells when treated with 
properdin or TSR4+5. In the initial stages of infection by 
M. bovis BCG, pretreated with properdin, during phagocytosis, 
the expression of TNF-α was significantly enhanced. Other pro-
inflammatory responses that were also elevated in the presence of 
properdin at initial stages of infection are IL-1β and IL-6. IL-1β is 
a mediator of inflammation and is required for host resistance to 
M. tuberculosis infection (45). IL-6 is a biomarker for tuberculo-
sis, as increased levels are observed in patients with tuberculosis 
(46) that is required for a T cell response against M. tuberculosis 
infection (47, 48). Conversely, IL-10, IL-12, and TGF-β were 
downregulated by properdin, thus suppressing the anti-inflam-
matory response. The downregulation of IL-12 by properdin 
in vivo may suppress the Th1 response. TSR4+5 was also able to 
mimic the cytokine response like properdin, suggesting that the 
modules responsible for the major part of the interaction with 
M. bovis BCG may be TSR4+5.
Macrophages play a significant role in the innate immune 
response to pathogens and so are also crucial for an adaptive 
immune response (49). However, M. tuberculosis can evade the 
innate immune defense, inhibiting phagosome maturation (36), 
resisting anti-microbial agents damaging the bacterial cell wall 
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and facilitating replication within the host and escaping early 
immune recognition. Thus, these pathogens interfere with the 
early immune response and the induction of pro-inflammatory 
cytokines (49).
IL-10 and TGF-β suppression by properdin may enhance the 
clearance of mycobacteria by the host during the early stages of 
M. tuberculosis infection. After phagocystosis of M. tuberculosis, 
IL-10 has been shown to block phagolysosome maturation  and 
antigen presentation by macrophages, thus aiding the survival of 
the pathogen (50, 51). Furthermore, IL-10 can inhibit the gen-
eration of reactive oxygen and nitrogen intermediates in IFN-γ 
activated macrophages, which are required for intracellular kill-
ing (52, 53). The enhanced levels of IL-10 and TGF-β in the lungs 
of active tuberculosis patients demonstrate a weakened immune 
response to M. tuberculosis, and hence, a role in the pathogenesis 
and disease progression (54, 55). VEGF was also found to be at 
a significantly higher level in tuberculosis patients with extrapul-
monary tuberculosis (EPTB) than those with pulmonary disease 
(56). In our study, properdin and TSR4+5 seems to result in a 
marked elevation of VEGF after 48 h. Since our data also shows 
that mycobacteria have a reduced phagocytosis by macrophages, 
the resulting extracellular bacteria may be encouraged by VEGF 
to disseminate. The beneficial effect of properdin may be to 
inhibit the mechanisms involved in evasion and, thus, facilitate a 
protective response against mycobacterial infection.
The downregulation of IL-12 by properdin or TSR4+5 may 
be due to the reduced phagocytosis of M. bovis BCG, thus, 
downregulating the Th1 response. This may be necessary for the 
Th1/Th2 homeostasis in the protective granuloma (41, 57, 58). 
Both IL-10 and TGF-β levels were supressed, whilst TNF-α was 
elevated during the first 24 h after phagocytosis.
Although M. bovis BCG shares 99% genome homology to M. 
tuberculosis, there are some genetic differences which lead to its 
avirulence. The major difference between M. bovis BCG and M. 
tuberculosis is the large genomic deletion RD1, which causes the 
loss of various virulent genes coding for proteins such as ESAT-6, 
CFP-10 and also a bacterial secretion system (59, 60). Therefore 
the findings in our study will need to be validated using virulent 
strains of M. tuberculosis.
Properdin deficiency renders the host susceptible to a range 
of bacterial infections, especially Neisseria species. Three types 
of properdin deficiency have been reported: type I (absence of 
the properdin protein), type 2 (low level of properdin about 1–10% 
found in the serum), and type 3 deficiency (normal levels of 
protein being produced, but functionally defective). The most 
commonly reported deficiency is the type I properdin deficiency 
that exhibits fulminant infections. The incidence of tuberculosis 
has not been reported in properdin deficient subjects, possibly 
due to the majority of studies being in Scandinavia or west-
ern Europe, in populations where there is a low incidence of 
tuberculosis.
The data in this study suggest that properdin, via TSR4+5, 
may help in the clearance of mycobacterial infection by circum-
venting pathogen immune evasion strategies by upregulating 
the pro-inflammatory response. Properdin may also promote 
the formation and maintenance of the protective granuloma. 
The data in this study give further insights into the involve-
ment of complement regulatory proteins in shaping the cellular 
immune response against mycobacteria in a complement 
activation-independent manner. Further studies are needed 
to fully characterize the nature and extent of involvement of 
properdin in tuberculosis pathogenesis, particularly in the early 
stages of infection.
The complement-independent interaction between human 
properdin and mycobacteria is a novel observation, which is 
independent of C3b deposition and aggregation of properdin 
(61). This is consistent with our recent study where we have 
shown that properdin can recognize chemical patterns on 
nanoparticles via TSR4+5 and modulate immune response 
by THP-1 cells (26) without involving complement activa-
tion/deposition. In conclusion, properdin may be involved 
in modulating host-pathogen interactions in tuberculosis. 
However, further studies are needed on pathogenic M. 
tuberculosis and in vivo, to understand the precise role of 
this complement regulatory protein in pathogenesis, which 
may give new insights into therapies against this formidable 
disease.
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